| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8771704 | The Journal of Urology | 2018 | 7 Pages |
Abstract
A high GEMCaP score was associated with biochemical recurrence in 2 external cohorts. This remained true after adjusting for clinical and pathological factors. The GEMCaP biomarker could be an efficient and effective clinical risk assessment tool to identify patients with prostate cancer for early adjuvant therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Hao G. Nguyen, Christopher Welty, Karla Lindquist, Vy Ngo, Elizabeth Gilbert, Henrik Bengtsson, Cristina Magi-Galluzzi, Jerome Jean-Gilles, Jorge Yao, Matthew Cooperberg, Edward Messing, Eric A. Klein, Peter R. Carroll, Pamela L. Paris,